What is the recommended treatment for Enterococcus faecium bloodstream infection?

Treatment of Enterococcus faecium Bloodstream Infection

For vancomycin-susceptible E. faecium BSI, use vancomycin or ampicillin as monotherapy; for vancomycin-resistant E. faecium (VRE) BSI, use linezolid 600 mg IV every 12 hours as first-line therapy for 10-14 days. 1

Initial Assessment and Antibiotic Selection

Vancomycin-Susceptible E. faecium

• Vancomycin is the preferred agent for vancomycin-susceptible strains 2
• Target vancomycin AUC24/MIC ratio ≥427 for optimal treatment success 3
• This pharmacodynamic target independently predicts treatment success (adjusted OR 4.4) without increasing nephrotoxicity 3
• Ampicillin is an alternative if susceptible

Vancomycin-Resistant E. faecium (VRE)

First-line options per guidelines:

• Linezolid 600 mg IV every 12 hours (strong recommendation, 1C) 1
• Daptomycin 8-12 mg/kg IV daily (alternative option) 1

Critical dosing considerations for daptomycin:

• If using daptomycin, dose ≥11 mg/kg is superior to 8 to <11 mg/kg, particularly when daptomycin MIC = 8 mg/L 4
• High-dose daptomycin (≥11 mg/kg) reduced 28-day mortality from 55% to 34% compared to standard dosing (adjusted OR 3.11 for mortality with lower doses) 4
• Inadequate daptomycin dosing (<10 mg/kg) was associated with 43% mortality versus 13% with adequate dosing in transplant patients 5
• Consider daptomycin-beta-lactam combination when daptomycin MIC is 3-4 mg/mL or for deep-seated infections 1, 6

Recent expert consensus refinements:

• For vanB VRE-BSI: teicoplanin is preferred 6
• For vanA VRE-BSI: both linezolid and high-dose daptomycin (>9 mg/kg/day) are effective 6
• Reserve daptomycin-based combinations for challenging cases (deep-seated infections, high MICs) 6

Treatment Duration

Standard duration: 10-14 days 1

Duration should be individualized based on:

• Source control achievement
• Presence of endocarditis (requires cardiac surgery consultation)
• Catheter-related BSI with device removal: consider short-course (<7 days) in uncomplicated cases 6
• Deep-seated infections may require longer therapy

Monitoring and Follow-up

• Assess response using clinical trends and inflammatory markers rather than routine follow-up blood cultures 6
• Use follow-up blood cultures specifically to confirm microbiological eradication when clinically indicated 6
• Monitor for daptomycin resistance development (21% developed resistance in one cohort) 5

Key Prognostic Factors

Mortality predictors to recognize:

• APACHE II score and Charlson comorbidity index 2
• Severity of illness/septic shock at presentation 7
• Impaired renal function 2
• Neutropenia 5
• Lack of source control 5
• Absence of appropriate anti-VRE therapy (adjusted OR 10.44 for mortality) 8

Overall mortality: 24-25% at 30 days 2, 8

Critical Pitfalls to Avoid

1. Underdosing daptomycin: Use ≥11 mg/kg for daptomycin-resistant VRE, not the standard 8-10 mg/kg 4
2. Subtherapeutic vancomycin exposure: Target AUC24/MIC ≥427, not just trough levels 3
3. Delayed appropriate therapy: Early active anti-VRE therapy significantly reduces mortality 8
4. Ignoring source control: Inadequate source control independently predicts mortality 5
5. Unnecessary combination therapy for E. faecalis: Monotherapy is non-inferior for non-endocarditis cases 7

Resistance Considerations

• E. faecium shows higher antimicrobial resistance than E. faecalis 2
• ST17 predominates (58%) with enhanced biofilm formation, though not independently associated with mortality 8
• All VRE isolates typically carry vanA gene 8